ARV Technologies


Advanced RNA Vaccine Technologies (ARV) has successfully established its RNA and LNP technologies since its founding in North Bethesda, Maryland, USA in 2021. Its first product, PanCOVAX, is a universal COVID19 mRNA vaccine that elicits potent neutralizing antibodies and T-cell immunity capable of providing broad protection against current and future variants of SARS-CoV-2, a platform also used as a strategy against other infectious diseases.
ARV has also developed an effective high-throughput platform to identify new compounds for RNA delivery in humans, and it has identified at least two sets of lipids that can effectively deliver RNA vaccines at 10-100 fold lower doses compared to currently marketed LNPs, but induce the same or higher immune responses.
In addition to developing HSV-2 and a cancer vaccine on its own, ARV is seeking to collaborate with other organizations to develop additional products.


For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall